Physician profile
Jonathan P Auth
NPI 1871639823
$2,723.65
in general payments reported to CMS, 2019-2025
26 companies · $840 in 2025
The $840 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $67.81 · 2021: $399 · 2022: $286 · 2023: $430 · 2024: $487 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $495.82 | 2023-2025 | Nayzilam, Briviact, Fintepla |
| Merck Sharp & Dohme LLC | $395.31 | 2020-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Tris Pharma INC | $385.34 | 2021-2025 | Quillichew Er, Dyanavel Xr, Quillivant |
| Ironshore Pharmaceuticals INC. | $247.45 | 2019-2023 | Jornay Pm |
| Glaxosmithkline, LLC. | $238.80 | 2019-2025 | Bexsero |
| Sanofi Pasteur INC. | $231.03 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $124.99 | 2021 | |
| Pfizer INC. | $116.34 | 2024-2025 | |
| Alk-Abello, INC | $59.21 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $54.75 | 2024 | |
| Genzyme Corporation | $47.20 | 2024 | |
| Supernus Pharmaceuticals, INC. | $47.12 | 2021 | |
| Novo Nordisk INC | $30.00 | 2025 | Wegovy |
| Cranial Technologies, INC | $29.96 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $29.08 | 2025 | Neffy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.55 | 2024 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $19.85 | 2019 | |
| Lnhc, INC | $19.38 | 2025 | Zelsuvmi |
| Nestle Healthcare Nutrition INC. | $18.61 | 2022 | |
| Seqirus USA INC | $17.76 | 2023 | Flucelvax Quadrivalent |
| Corium, LLC | $16.33 | 2021 | |
| Organon LLC | $14.79 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $14.28 | 2023 | Kristalose |
| Verrica Pharmaceuticals INC. | $13.81 | 2023 | Ycanth |
| Aytu Biopharma, INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Auth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.